The effect of risankizumab on achieving minimal clinically important differences in patient-reported outcomes in patients with psoriatic arthritis: results from KEEPsAKE 1 and 2.
L E KristensenA M SolimanKim A PappL BarcombA EldredA ÖstörPublished in: Journal of the European Academy of Dermatology and Venereology : JEADV (2022)
These data demonstrate that patients with PsA receiving RZB treatment are more likely to report clinically important improvements in PROs compared with patients receiving PBO.